澳大利亚批准快速梅毒测试,供全国使用,以防治不断上升的病例,改善母婴健康。 Australia approves rapid syphilis test for nationwide use to combat rising cases and improve maternal and infant health.

澳大利亚已批准进行生物医学的iStatis Syphilis Antibody测试,供全国使用,并将其列入治疗物品登记册(ARTG:515126)。 Australia has approved bioLytical’s iStatis Syphilis Antibody Test for nationwide use, adding it to the Register of Therapeutic Goods (ARTG: 515126). 快速的护理点测试从手指尖血样样本中检测出梅毒抗体,在15分钟内产生结果。 The rapid, point-of-care test detects syphilis antibodies from a fingerstick blood sample, delivering results in under 15 minutes. 它是便携式的,在室温下稳定,不需要冷藏或复杂的设备,因此适合偏远和服务不足的诊所。 It is portable, stable at room temperature, and requires no cold storage or complex equipment, making it suitable for remote and underserved clinics. 在梅毒发病率上升——2024年报告了5,866例病例,比2014年的水平增加了一倍——以及先天性梅毒病例和婴儿死亡人数不断增加的情况下,该测试支持早期诊断。 The test supports early diagnosis amid rising syphilis rates—5,866 cases reported in 2024, double the 2014 level—and a growing number of congenital syphilis cases and infant deaths. 它的纳入加强了公共卫生工作,以遏制传播,改善孕产妇和婴儿的成果。 Its inclusion strengthens public health efforts to curb transmission and improve maternal and infant outcomes. 保健服务提供者可以通过经授权的经销商或直接从生物药品处获得检验。 Healthcare providers can obtain the test through authorized distributors or directly from bioLytical.